CIPLA vs IPCALAB: Stock Comparison

Cipla Ltd vs IPCA Laboratories Limited

Live data: 22 July 2026, 2:36 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Cipla Ltd shows a lower P/E, a higher dividend yield and lower leverage, while IPCA Laboratories Limited shows a higher ROE, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Cipla Ltd and IPCA Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CIPLA is more favourable on 7 of 13 scored metrics and IPCALAB on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹45,033 Cr
P/E Ratio
CIPLA has a lower P/E
29.83x vs 39.94x
P/B Ratio
CIPLA has a lower P/B
3.36x vs 5.65x
EPS
CIPLA has higher earnings per share
₹48.01 vs ₹45.05
Dividend Yield
CIPLA has a higher dividend yield
0.9% vs 0.33%
Revenue Growth (TTM YoY)
IPCALAB has faster revenue growth
6.2% vs -2.1%
EPS Growth (TTM YoY)
IPCALAB has faster EPS growth
341.6% vs -54.6%
Qtr Sales Growth
IPCALAB has stronger quarterly sales growth
6.31% vs -2.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCIPLAIPCALAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCIPLAIPCALAB
Live Price₹1,411.6₹1,780
Day Change-1.46%-1.06%
Volume12.9 L1.38 L
52-Week High₹1,673₹1,944.9
52-Week Low₹1,165.7₹1,251.6
Distance from 52W High-15.62%-8.48%

Valuation

MetricCIPLAIPCALAB
Market Cap₹1.14 L Cr₹45,033 Cr
P/E Ratio29.83x39.94x
P/B Ratio3.36x5.65x
EPS₹48.01₹45.05
Book Value₹426.25₹317.84
Dividend Yield0.9%0.33%

Growth

MetricCIPLAIPCALAB
Revenue Growth (TTM YoY)-2.1%6.2%
EPS Growth (TTM YoY)-54.6%341.6%
Qtr Sales Growth-2.8%6.31%
Qtr Profit Growth-54.6%80.9%

Profitability & Leverage

MetricCIPLAIPCALAB
ROE11.6%16%
ROCE15.5%17.3%
Net Margin13.96%11.83%
Operating Margin20.9%20.5%
Debt to Equity0.02x0.1x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricCIPLAIPCALAB
Promoter Holding9.17%44.72%
FII Holding22.56% 1.37 pp10.73% 0.1 pp
DII Holding31.97% 1.25 pp37.37% 0.08 pp
Public Holding16.25% 0.12 pp7.18% 0.02 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Cipla Ltd and IPCA Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.